Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells.
| Komentáře: | Erratum in: Nat Immunol 2001 Apr;2(4):368. |
|---|---|
| References: | Br J Haematol. 1999 Mar;104(3):589-99. (PMID: 10086799) J Immunol. 1999 May 1;162(9):5327-36. (PMID: 10228008) Cell. 1993 Jul 2;73(7):1349-60. (PMID: 8391931) Blood. 2000 Nov 1;96(9):3168-74. (PMID: 11049999) Cancer Res. 1997 Nov 1;57(21):4940-7. (PMID: 9354461) Leukemia. 1998 Oct;12(10):1573-82. (PMID: 9766502) J Immunol. 1979 Mar;122(3):1087-90. (PMID: 376702) J Immunol. 1999 Mar 15;162(6):3327-35. (PMID: 10092786) Nature. 1999 Mar 25;398(6725):341-4. (PMID: 10192335) Cell. 1997 Jul 25;90(2):373-83. (PMID: 9244310) J Exp Med. 1998 Jan 5;187(1):123-8. (PMID: 9419218) Blood. 1993 Apr 15;81(8):2076-84. (PMID: 8386026) Genes Dev. 1997 Nov 1;11(21):2810-21. (PMID: 9353251) J Exp Med. 1996 Feb 1;183(2):669-74. (PMID: 8627180) J Immunol. 1997 Mar 1;158(5):2090-8. (PMID: 9036953) EMBO J. 1999 Dec 1;18(23):6694-704. (PMID: 10581243) Cancer Immunol Immunother. 2000 Jun;49(3):173-80. (PMID: 10881697) Science. 1994 Jun 10;264(5165):1587-9. (PMID: 8202711) Blood. 1991 Oct 15;78(8):1901-14. (PMID: 1912574) Immunity. 1999 Sep;11(3):379-89. (PMID: 10514016) Am J Hematol. 1987 Jun;25(2):131-42. (PMID: 2955695) J Immunol. 2000 Dec 15;165(12 ):6703-9. (PMID: 11120787) Nat Med. 1997 Sep;3(9):984-9. (PMID: 9288724) EMBO J. 1999 Jun 1;18(11):3034-43. (PMID: 10357816) Blood. 1989 Mar;73(4):1016-9. (PMID: 2784065) Immunity. 1996 Jul;5(1):31-40. (PMID: 8758892) Biochem Biophys Res Commun. 1999 Mar 24;256(3):620-5. (PMID: 10080948) Eur J Immunol. 1999 Dec;29(12):3908-13. (PMID: 10601998) Annu Rev Immunol. 1998;16:111-35. (PMID: 9597126) Science. 1995 Sep 8;269(5229):1424-7. (PMID: 7544915) J Immunol. 1999 Dec 15;163(12):6386-92. (PMID: 10586028) J Immunol. 1993 Dec 1;151(11):5896-906. (PMID: 8245437) Br J Haematol. 1994 Mar;86(3):496-504. (PMID: 8043432) Immunity. 1998 Aug;9(2):247-56. (PMID: 9729045) Blood. 1996 Jun 15;87(12):4990-7. (PMID: 8652811) Immunol Today. 1995 Feb;16(2):76-80. (PMID: 7888070) Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1421-6. (PMID: 9990039) J Exp Med. 1994 Mar 1;179(3):999-1004. (PMID: 8113691) Cell. 1996 Feb 23;84(4):551-62. (PMID: 8598042) J Immunol. 2000 Jul 15;165(2):786-94. (PMID: 10878352) J Exp Med. 1998 Jul 20;188(2):297-304. (PMID: 9670042) J Immunol. 2000 Nov 1;165(9):5105-11. (PMID: 11046041) Blood. 1998 Jun 1;91(11):4273-81. (PMID: 9596676) Adv Immunol. 1996;61:79-146. (PMID: 8834495) J Exp Med. 2000 Feb 21;191(4):651-60. (PMID: 10684857) Adv Immunol. 1996;61:1-77. (PMID: 8834494) J Immunol. 2000 Aug 1;165(3):1175-81. (PMID: 10903714) J Immunol. 2000 Feb 15;164(4):2200-6. (PMID: 10657675) Blood. 1997 Mar 15;89(6):2048-59. (PMID: 9058727) |
| Grant Information: | AR40908 United States AR NIAMS NIH HHS; R01 AR040908 United States AR NIAMS NIH HHS; T32 AI 07621 United States AI NIAID NIH HHS; T32 AI007621 United States AI NIAID NIH HHS; R56 AI045011 United States AI NIAID NIH HHS; AG 13910 United States AG NIA NIH HHS; R01 AI045011 United States AI NIAID NIH HHS; AI 45011 United States AI NIAID NIH HHS |
| Substance Nomenclature: | 0 (CD28 Antigens) 0 (CD30 Ligand) 0 (CD40 Antigens) 0 (CD8 Antigens) 0 (DNA Primers) 0 (Immunoglobulin A) 0 (Immunoglobulin G) 0 (Ki-1 Antigen) 0 (Membrane Glycoproteins) 0 (OX40 Ligand) 0 (Receptors, Tumor Necrosis Factor) 0 (TNFSF4 protein, human) 0 (TNFSF8 protein, human) 207137-56-2 (Interleukin-4) |
| Entry Date(s): | Date Created: 20010329 Date Completed: 20010412 Latest Revision: 20240610 |
| Update Code: | 20240610 |
| PubMed Central ID: | PMC4621971 |
| DOI: | 10.1038/84254 |
| PMID: | 11175813 |
| Autor: | Cerutti A; Division of Molecular Immunology, Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA. acerutti@med.cornell.edu, Kim EC, Shah S, Schattner EJ, Zan H, Schaffer A, Casali P |
| Jazyk: | angličtina |
| Zdroj: | Nature immunology [Nat Immunol] 2001 Feb; Vol. 2 (2), pp. 150-6. |
| DOI: | 10.1038/84254 |
| Abstrakt: | Chronic lymphocytic leukemia (CLL) is associated with impaired immunoglobulin (Ig) class-switching from IgM to IgG and IgA, a defect that leads to recurrent infections. When activated in the presence of leukemic CLL B cells, T cells rapidly up-regulate CD30 through an OX40 ligand and interleukin 4 (IL-4)-dependent mechanism. These leukemia-induced CD30+ T cells inhibit CD40 ligand (CD40L)-mediated S mu-->S gamma and S mu-->S alpha class-switch DNA recombination (CSR) by engaging CD30 ligand (CD30L), a molecule that interferes with the assembly of the CD40-tumor necrosis factor receptor-associated factor (TRAF) complex in nonmalignant IgD+ B cells. In addition, engagement of T cell CD30 by CD30L on neoplastic CLL B cells down-regulates the CD3-induced expression of CD40L. These findings indicate that, in CLL, abnormal CD30-CD30L interaction impairs IgG and IgA production by interfering with the CD40-mediated differentiation of nonmalignant B cells. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|